Evodiamine synergizes with doxorubicin in the treatment of chemoresistant human breast cancer without inhibiting P-glycoprotein

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Wang, Shengpeng ^a   Wang, Lu ^a   Shi, Zhi ^b   Zhong, Zhangfeng ^a   Chen, Meiwan ^a   Wang, Yitao ^a  

^a China Macau University of Science and Technology Zhuhai MUST Science and Technology Research Institute   (Macao)

^b JINAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 7; CASPASE 9; DOXORUBICIN; EVODIAMINE; INHIBITOR OF APOPTOSIS PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MULTIDRUG RESISTANCE PROTEIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAS PROTEIN; CASPASE; HERBACEOUS AGENT; LACTATE DEHYDROGENASE; QUINAZOLINE DERIVATIVE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; MCF 7 CELL LINE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BREAST TUMOR; CHINESE MEDICINE; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY;

APOPTOSIS; BREAST NEOPLASMS; CASPASES; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; L-LACTATE DEHYDROGENASE; MCF-7 CELLS; MEDICINE, CHINESE TRADITIONAL; P-GLYCOPROTEIN; POLY(ADP-RIBOSE) POLYMERASES; QUINAZOLINES; SIGNAL TRANSDUCTION;

EID: 84901314991     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0097512     Document Type: Article

References (45)

1. Vaux DL, Silke J (2005) IAPs - the ubiquitin connection. Cell Death Differ 12: 1205-1207. (Pubitemid 41195106)
2. Wang Z, Li Y, Ahmad A, Azmi AS, Kong D, et al. (2010) Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist Updat 13: 109-118.
3. Kruh GD (2003) Introduction to resistance to anticancer agents. Oncogene 22: 7262-7264.
4. Krakstad C, Chekenya M (2010) Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics. Mol Cancer 9: 135.
5. Bratton SB, Walker G, Srinivasula SM, Sun XM, Butterworth M, et al. (2001) Recruitment, activation and retention of caspases-9 and -3 by Apaf-1 apoptosome and associated XIAP complexes. EMBO J 20: 998-1009. (Pubitemid 32186791)
6. Plenchette S, Cathelin S, Rebe C, Launay S, Ladoire S, et al. (2004) Translocation of the inhibitor of apoptosis protein c-IAP1 from the nucleus to the Golgi in hematopoietic cells undergoing differentiation: a nuclear export signal-mediated event. Blood 104: 2035-2043. (Pubitemid 39297854)
7. Lu M, Lin SC, Huang Y, Kang YJ, Rich R, et al. (2007) XIAP induces NF-kappaB activation via the BIR1/TAB1 interaction and BIR1 dimerization. Mol Cell 26: 689-702. (Pubitemid 46856243)
8. Rumjanek VM, Vidal RS, Maia RC (2013) Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR-CML cell lines? Biosci Rep 33: 875-888.
9. Silva KL, de Souza PS, Nestal de Moraes G, Moellmann-Coelho A, Vasconcelos Fda C, et al. (2013) XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells. Leuk Res 37: 1350-1358.
10. Fulda S, Vucic D (2012) Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Discov 11: 109-124.
11. McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, et al. (2011) Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226: 2762-2781.
12. Steelman LS, Chappell WH, Abrams SL, Kempf RC, Long J, et al. (2011) Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) 3: 192-222.
13. McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Franklin RA, et al. (2012) Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget 3: 1068-1111.
14. McCubrey JA, LaHair MM, Franklin RA (2006) Reactive oxygen species-induced activation of the MAP kinase signaling pathways. Antioxidants & Redox Signaling 8: 1775-1789. (Pubitemid 44726351)
15. King CL, Kong YC, Wong NS, Yeung HW, Fong HH, et al. (1980) Uterotonic effect of Evodia rutaecarpa alkaloids. J Nat Prod 43: 577-582.
16. Fei XF, Wang BX, Li TJ, Tashiro S, Minami M, et al. (2003) Evodiamine, a constituent of Evodiae Fructus, induces anti-proliferating effects in tumor cells. Cancer Sci 94: 92-98. (Pubitemid 36575865)
17. Ogasawara M, Matsunaga T, Takahashi S, Saiki I, Suzuki H (2002) Anti-invasive and metastatic activities of evodiamine. Biol Pharm Bull 25: 1491-1493. (Pubitemid 39663174)
18. Shyu KG, Lin S, Lee CC, Chen E, Lin LC, et al. (2006) Evodiamine inhibits in vitro angiogenesis: Implication for antitumorgenicity. Life Sci 78: 2234-2243.
19. Takada Y, Kobayashi Y, Aggarwal BB (2005) Evodiamine abolishes constitutive and inducible NF-kappaB activation by inhibiting IkappaBalpha kinase activation, thereby suppressing NF-kappaB-regulated antiapoptotic and metastatic gene expression, up-regulating apoptosis, and inhibiting invasion. J Biol Chem 280: 17203-17212. (Pubitemid 41389187)
20. Yu H, Jin H, Gong W, Wang Z, Liang H (2013) Pharmacological actions of multi-target-directed evodiamine. Molecules 18: 1826-1843.
21. Yang J, Wu LJ, Tashino S, Onodera S, Ikejima T (2008) Reactive oxygen species and nitric oxide regulate mitochondria-dependent apoptosis and autophagy in evodiamine-treated human cervix carcinoma HeLa cells. Free Radic Res 42: 492-504. (Pubitemid 351935163)
22. Lee TJ, Kim EJ, Kim S, Jung EM, Park JW, et al. (2006) Caspase-dependent and caspase-independent apoptosis induced by evodiamine in human leukemic U937 cells. Mol Cancer Ther 5: 2398-2407. (Pubitemid 44530477)
23. Wang C, Li S, Wang MW (2010) Evodiamine-induced human melanoma A375-S2 cell death was mediated by PI3K/Akt/caspase and Fas-L/NF-kappa B signaling pathways and augmented by ubiquitin-proteasome inhibition. Toxicology in Vitro 24: 898-904.
24. Batist G, Tulpule A, Sinha BK, Katki AG, Myers CE, et al. (1986) Overexpression of a novel anionic glutathione transferase in multidrug-resistant human breast cancer cells. J Biol Chem 261: 15544-15549. (Pubitemid 17208781)
25. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, et al. (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48: 4827-4833.
26. Chen SY, Hu SS, Dong Q, Cai JX, Zhang WP, et al. (2013) Establishment of Paclitaxel-resistant Breast Cancer Cell Line and Nude Mice Models, and Underlying Multidrug Resistance Mechanisms in Vitro and in Vivo. Asian Pac J Cancer Prev 14: 6135-6140.
27. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC (1994) Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE. Nature 371: 346-347. (Pubitemid 24300618)
28. Kan SF, Huang WJ, Lin LC, Wang PS (2004) Inhibitory effects of evodiamine on the growth of human prostate cancer cell line LNCaP. Int J Cancer 110: 641-651. (Pubitemid 38746021)
29. Blanc C, Deveraux QL, Krajewski S, Janicke RU, Porter AG, et al. (2000) Caspase-3 is essential for procaspase-9 processing and cisplatin-induced apoptosis of MCF-7 breast cancer cells. Cancer Research 60: 4386-4390. (Pubitemid 32103616)
30. Essmann F, Engels IH, Totzke G, Schulze-Osthoff K, Janicke RU (2004) Apoptosis resistance of MCF-7 breast carcinoma cells to ionizing radiation is independent of p53 and cell cycle control but caused by the lack of caspase-3 and a caffeine-inhibitable event. Cancer Research 64: 7065-7072. (Pubitemid 39331018)
31. Chou TC, Talaly P (1977) A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems. J Biol Chem 252: 6438-6442. (Pubitemid 8193791)
32. Rangwala F, Williams KP, Smith GR, Thomas Z, Allensworth JL, et al. (2012) Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer 12: 402.
33. Saha S, Adhikary A, Bhattacharyya P, Das T, Sa G (2012) Death by design: where curcumin sensitizes drug-resistant tumours. Anticancer Res 32: 2567-2584.
34. Dai Y, Lawrence TS, Xu L (2009) Overcoming cancer therapy resistance by targeting inhibitors of apoptosis proteins and nuclear factor-kappa B. Am J Transl Res 1: 1-15.
35. Yamaguchi Y, Shiraki K, Fuke H, Inoue T, Miyashita K, et al. (2005) Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 14: 1311-1316.
36. Chawla-Sarkar M, Bae SI, Reu FJ, Jacobs BS, Lindner DJ, et al. (2004) Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 11: 915-923. (Pubitemid 39139750)
37. Molnar J, Engi H, Hohmann J, Molnar P, Deli J, et al. (2010) Reversal of Multidrug Resistance by Natural Substances from Plants. Current Topics in Medicinal Chemistry 10: 1757-1768.
38. Peng XH, Karna P, O'Regan RM, Liu X, Naithani R, et al. (2007) Downregulation of inhibitor of apoptosis proteins by deguelin selectively induces apoptosis in breast cancer cells. Mol Pharmacol 71: 101-111. (Pubitemid 46023420)
39. Jia J, Zhu F, Ma X, Cao Z, Li Y, et al. (2009) Mechanisms of drug combinations: interaction and network perspectives. Nat Rev Drug Discov 8: 111-128.
40. Keith CT, Borisy AA, Stockwell BR (2005) Multicomponent therapeutics for networked systems. Nat Rev Drug Discov 4: 71-78. (Pubitemid 40109591)
41. Wang H, Zhao Y, Wu Y, Hu YL, Nan K, et al. (2011) Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32: 8281-8290.
42. Hu CM, Zhang L (2012) Nanoparticle-based combination therapy toward overcoming drug resistance in cancer. Biochem Pharmacol 83: 1104-1111.
43. L'Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, et al. (2006) DNA damage is an early event in doxorubicin-induced cardiac myocyte death. American Journal of Physiology-Heart and Circulatory Physiology 291: H1273-H1280. (Pubitemid 44343672)
44. Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, et al. (2014) Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochimica et biophysica acta 1840: 615-625.
45. Khonkarn R, Mankhetkorn S, Talelli M, Hennink WE, Okonogi S (2012) Cytostatic effect of xanthone-loaded mPEG-b-p(HPMAm-Lac2) micelles towards doxorubicin sensitive and resistant cancer cells. Colloids Surf B Biointerfaces 94: 266-273.